文献速递临床试验与 GCP流行病学与生物统计

儿童肿瘤随机对照治疗试验中的临床显著性:系统综述

Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review.
PubMed 文献 · Trials · 2018-10-05

该系统综述评估儿童肿瘤随机对照试验(RCT)中临床显著性的报告情况,包括治疗效应与样本量计算中delta值的关系,以及统计学显著性与临床显著性的一致性。共纳入77项RCT(11项非劣效和66项优效),代表95个随机化问题。结果显示少数随机化问题基于临床显著性得出结论,仅4.2%明确将delta值基于最小临床重要差异(MCID);在优效性试验中,统计学不显著的问题有25.5%可能具有临床显著性,而统计学显著的问题仅8.3%肯定具有临床显著性。

要点

  • 仅4.2%的随机化问题明确将delta值基于MCID。
  • 22.1%的随机化问题基于临床显著性得出结论。
  • 统计学不显著的研究中25.5%可能具有临床显著性。

核心结论

  • 少数儿童肿瘤RCT报告了与临床显著性相关的方法学属性。
  • 相当一部分统计学不显著的研究可能具有临床显著性。

研究设计与样本

  • 系统综述纳入报告或可计算样本量delta值的儿童肿瘤治疗RCT。
  • 检索MEDLINE、EMBASE和Cochrane对照试验中心注册库至2016年7月。
  • 共纳入77项RCT(11项非劣效和66项优效),代表95个随机化问题。

主要发现

  • 22.1%的随机化问题基于临床显著性得出结论(非劣效76.9%,优效13.4%)。
  • 仅4.2%明确将delta值基于MCID(非劣效15.4%,优效2.4%)。
  • 67.4%报告了主要结局实验组和对照组值的置信区间或标准误(非劣效92.3%,优效63.4%)。
  • 12.6%报告了治疗效应(非劣效46.2%,优效7.3%)。
  • 优效性试验中47个统计学不显著问题里25.5%可能临床显著;24个统计学显著问题里仅8.3%肯定临床显著。

关键数值与推荐

  • 22.1%的随机化问题基于临床显著性得出结论。
  • 4.2%的随机化问题明确将delta值基于MCID。
  • 67.4%的随机化问题报告了主要结局实验组和对照组值的置信区间或标准误。
  • 12.6%的随机化问题报告了治疗效应。
  • 优效性试验中统计学不显著问题25.5%可能临床显著,统计学显著问题8.3%肯定临床显著。

临床怎么用

  • 儿童肿瘤RCT设计应明确将MCID作为delta值依据。
  • 结果解释需结合临床显著性,避免仅依赖统计学显著性。
  • 应规范报告治疗效应及其置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical significance in a randomized controlled trial (RCT) can be determined using the minimal clinically important difference (MCID), which should inform the delta value used to determine sample size. The primary objective was to assess clinical significance in the pediatric oncology randomized controlled trial (RCT) treatment literature by evaluating: (1) the relationship between the treatment effect and the delta value as reported in the sample size calculation, and (2) the concordance between statistical and clinical significance. The secondary objective was to evaluate the reporting of methodological attributes related to clinical significance. METHODS: RCTs of pediatric cancer treatments, where a sample size calculation with a delta value was reported or could be calculated, were systematically reviewed. MEDLINE, EMBASE, and the Cochrane Childhood Cancer Group Specialized Register through CENTRAL were searched from inception to July 2016. RESULTS: RCTs (77 overall; 11 and 66), representing 95 (13 and 82) randomized questions were included for non-inferiority and superiority RCTs (herein, respectively). The minority (22.1% overall; 76.9 and 13.4%) of randomized questions reported conclusions based on clinical significance, and only 4.2% (15.4 and 2.4%) explicitly based the delta value on the MCID. Over half (67.4% overall; 92.3 and 63.4%) reported a confidence interval or standard error for the primary outcome experimental and control values and 12.6% (46.2 and 7.3%) reported the treatment effect, respectively. Of the 47 randomized questions in superiority trials that reported statistically non-significant findings, 25.5% were possibly clinically significant. Of the 24 randomized questions in superiority trials that were statistically significant, only 8.3% were definitely clinically significant. CONCLUSIONS: A minority of RCTs in the pediatric oncology literature reported methodological attributes related to clinical significance and a notable portion of statistically insignificant studies were possibly clinically significance.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Howard AF, Goddard K, Rassekh SR, et al. Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review. Trials. 2018. PMID: 30290839. doi:10.1186/s13063-018-2925-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。